Welcome to LookChem.com Sign In|Join Free
  • or
1-(2-Phenylpropyl)-3-(1,3-thiazol-2-yl)thiourea is a chiral thiourea derivative belonging to the PETT (phenylethylthiazolylthiourea) class of compounds, which function as non-nucleoside reverse transcriptase inhibitors (NNRTIs) against HIV-1. The 'R' stereoisomer of 1-(2-phenylpropyl)-3-(1,3-thiazol-2-yl)thiourea exhibits significantly higher potency than its 'S' counterpart, as it better fits the asymmetric binding pocket of HIV-1 RT, leading to lower IC50 values and enhanced inhibition of viral replication in human PBMCs. Additionally, it demonstrates superior activity against NNRTI-resistant HIV-1 strains, including mutants like Y181C and Y181C/K103N, compared to standard drugs like nevirapine. The anti-HIV efficacy of 1-(2-phenylpropyl)-3-(1,3-thiazol-2-yl)thiourea is strongly influenced by both stereochemistry and regiochemistry, with optimal activity linked to the 'R' configuration and specific structural features.

149486-09-9

Post Buying Request

149486-09-9 Suppliers

Recommended suppliers

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

149486-09-9 Usage

Check Digit Verification of cas no

The CAS Registry Mumber 149486-09-9 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,4,9,4,8 and 6 respectively; the second part has 2 digits, 0 and 9 respectively.
Calculate Digit Verification of CAS Registry Number 149486-09:
(8*1)+(7*4)+(6*9)+(5*4)+(4*8)+(3*6)+(2*0)+(1*9)=169
169 % 10 = 9
So 149486-09-9 is a valid CAS Registry Number.

149486-09-9Downstream Products

149486-09-9Relevant academic research and scientific papers

Effect of stereochemistry on the anti-HIV activity of chiral thiourea compounds

Venkatachalam,Mao,Uckun, Fatih M.

, p. 4275 - 4284 (2004)

Chiral derivatives of several substituted halopyridyl and thiazolyl PETT compounds were synthesized as non-nucleoside inhibitors of the reverse transcriptase (RT) enzyme (NNRTI) of the human immunodeficiency virus (HIV-1). Molecular modeling studies indic

Effect of stereo and regiochemistry towards wild and multidrug resistant HIV-1 virus: Viral potency of chiral PETT derivatives

Venkatachalam, Taracad K.,Mao, Chen,Uckun, Fatih M.

, p. 1933 - 1946 (2004)

Chiral derivatives of several substituted halopyridyl and thiazolyl PETT compounds were synthesized as non-nucleoside inhibitors of the reverse transcriptase (RT) enzyme of the human immunodeficiency virus (HIV-1). Molecular modeling studies indicated that because of the asymmetric geometry of the non-nucleoside inhibitors (NNRTI) binding pocket, the 'R' stereoisomers would fit the NNRTI binding pocket of the HIV-1 RT much better than the corresponding 'S' stereoisomers, as reflected by their 104-fold lower Ki values. The 'R' stereoisomers of several PETT derivatives inhibited the recombinant RT in vitro with lower IC50 values than their enantiomers. The active compounds were further evaluated for their ability to inhibit HIV-1 replication in human peripheral blood mononuclear cells (PBMCs). All the 'R' isomers again showed potent anti-HIV activity and inhibited the replication of the HIV-1 strains HTLVIIIB in PBMCs at nanomolar concentrations whereas their enantiomers were less potent. The lead compounds for the respective groups were further tested against A17 (NNRTI-resistant, Y181C mutant RT), and A17Var (NNI-resistant Y181C±K103N mutant RT) as well as multidrug resistant viral strains. The results indicated that the lead compounds were several logs more potent than the standard NNRTI drug nevirapine. Structure-activity relationship among the derivatives showed preference of pyridyl unit with halo substitutions primarily at 5-position demonstrating the importance of both the stereochemistry as well as regiochemistry. Our data provides experimental evidence that the stereochemistry and the regiochemistry of non-nucleoside inhibitors can profoundly affect their anti-HIV activity.

Phenethylthiazolethiourea (PETT) compounds, a new class of HIV-1 reverse transcriptase inhibitors. 1. Synthesis and basic structure-activity relationship studies of PETT analogs

Bell,Cantrell,Hogberg,Jaskunas,Johansson,Jordan,Kinnick,Lind,Morin Jr.,Noreen,Oberg,Palkowitz,Parrish,Pranc,Sahlberg,Ternansky,Vasileff,Vrang,West,et al.

, p. 4929 - 4936 (2007/10/03)

A novel series of potent specific HIV-1 inhibitory compounds is described. The lead compound in the series, N-(2-phenethyl)-N'-(2-thiazolyl)thiourea (1), inhibits HIV-1 RT using rCdG as the template with an IC50 of 0.9 μM. In MT-4 cells, compound 1 inhibits HIV-1 with an ED50 of 1.3 μM. The 50% cytotoxic dose in cell culture is >380 μM. The chemical structure-activity relationship (SAR) was developed by notionally dividing the lead compound in four quadrants. The SAR strategy had two phases. The first phase involved optimization of antiviral activity through independent variation of quadrants 1-4. The second phase involved the preparation of hybrid structures combining the best of these substituents. Further SAR studies and pharmacokinetic considerations led to the identification of N-(2-pyridyl)-N'-(5-bromo-2- pyridyl)-thiourea (62; LY300046 · HCl) as a candidate for clinical evaluation. LY300046 · HCl inhibits HIV-1 RT with an IC50 of 15 nM and in cell culture has an ED50 of 20 nM.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1 Customer Service

What can I do for you?
Get Best Price

Get Best Price for 149486-09-9